Efficacy of Venetoclax Combined with Azacitidine in Elderly Patients with Relapsed Acute Myeloid Leukemia.

ABSTRACT:

Background

Elderly patients with relapsed acute myeloid leukemia (AML) have limited treatment options and a poor prognosis. Venetoclax combined with azacitidine has shown promising activity in newly diagnosed or relapsed/refractory AML, but real-world data on older populations remain scarce. This study aimed to evaluate the efficacy, safety, and prognostic factors - including select blood biomarkers - of venetoclax plus azacitidine in elderly patients with relapsed AML.

Methods

We conducted a single-center retrospective review of patients aged ≥65 years diagnosed with relapsed AML who received venetoclax plus azacitidine between January 2018 and December 2022. Patient demographics, baseline disease characteristics, and treatment details were collected. Blood biomarkers, such

SUBMITTER: Yan M 

PROVIDER: S-EPMC12422247 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature